Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Radiosynthesis and PET Bioimaging of 76Br-Bedaquiline in a Murine Model of Tuberculosis.

Ordonez AA, Carroll LS, Abhishek S, Mota F, Ruiz-Bedoya CA, Klunk MH, Singh AK, Freundlich JS, Mease RC, Jain SK.

ACS Infect Dis. 2019 Jul 29. doi: 10.1021/acsinfecdis.9b00207. [Epub ahead of print]

PMID:
31345032
2.

Preclinical evaluation of 203/212Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer.

Ray Banerjee S, Minn IL, Kumar V, Josefsson A, Lisok A, Brummet M, Chen J, Kiess A, Baidoo K, Brayton C, Mease RC, Brechbiel M, Sgouros G, Hobbs RF, Pomper MG.

J Nucl Med. 2019 Jun 28. pii: jnumed.119.229393. doi: 10.2967/jnumed.119.229393. [Epub ahead of print]

PMID:
31253744
3.

Iodination of terminal alkynes using KI/CuSO4 - A facile method with potential for radio-iodination.

Ferris T, Carroll L, Mease RC, Spivey AC, Aboagye EO.

Tetrahedron Lett. 2019 Mar 28;60(13):936-939. doi: 10.1016/j.tetlet.2019.02.041.

4.

Development of [18F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide.

Lesniak WG, Mease RC, Chatterjee S, Kumar D, Lisok A, Wharram B, Kalagadda VR, Emens LA, Pomper MG, Nimmagadda S.

Mol Imaging. 2019 Jan-Dec;18:1536012119852189. doi: 10.1177/1536012119852189.

5.

A comparison of prostate cancer bone metastases on 18F-Sodium Fluoride and Prostate Specific Membrane Antigen (18F-PSMA) PET/CT: Discordant uptake in the same lesion.

Harmon SA, Mena E, Shih JH, Adler S, McKinney Y, Bergvall E, Mehralivand S, Sowalsky AG, Couvillon A, Madan RA, Gulley JL, Eary J, Mease RC, Pomper MG, Dahut WL, Turkbey B, Lindenberg L, Choyke PL.

Oncotarget. 2018 Dec 28;9(102):37676-37688. doi: 10.18632/oncotarget.26481. eCollection 2018 Dec 28.

6.

Positron Emission Tomography Imaging with 2-[18F]F- p-Aminobenzoic Acid Detects Staphylococcus aureus Infections and Monitors Drug Response.

Zhang Z, Ordonez AA, Wang H, Li Y, Gogarty KR, Weinstein EA, Daryaee F, Merino J, Yoon GE, Kalinda AS, Mease RC, Iuliano JN, Smith-Jones PM, Jain SK, Tonge PJ.

ACS Infect Dis. 2018 Nov 9;4(11):1635-1644. doi: 10.1021/acsinfecdis.8b00182. Epub 2018 Aug 17.

7.

Radioligand Therapy of Prostate Cancer with a Long-Lasting Prostate-Specific Membrane Antigen Targeting Agent 90Y-DOTA-EB-MCG.

Wang Z, Jacobson O, Tian R, Mease RC, Kiesewetter DO, Niu G, Pomper MG, Chen X.

Bioconjug Chem. 2018 Jul 18;29(7):2309-2315. doi: 10.1021/acs.bioconjchem.8b00292. Epub 2018 Jun 15.

8.

A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-Targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer.

Harmon SA, Bergvall E, Mena E, Shih JH, Adler S, McKinney Y, Mehralivand S, Citrin DE, Couvillon A, Madan RA, Gulley JL, Mease RC, Jacobs PM, Pomper MG, Turkbey B, Choyke PL, Lindenberg ML.

J Nucl Med. 2018 Nov;59(11):1665-1671. doi: 10.2967/jnumed.117.207373. Epub 2018 Mar 30.

9.

Clinical impact of PSMA-based 18F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy.

Mena E, Lindenberg ML, Shih JH, Adler S, Harmon S, Bergvall E, Citrin D, Dahut W, Ton AT, McKinney Y, Weaver J, Eclarinal P, Forest A, Afari G, Bhattacharyya S, Mease RC, Merino MJ, Pinto P, Wood BJ, Jacobs P, Pomper MG, Choyke PL, Turkbey B.

Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):4-11. doi: 10.1007/s00259-017-3818-x. Epub 2017 Sep 11.

PMID:
28894899
10.

18F-DCFBC Prostate-Specific Membrane Antigen-Targeted PET/CT Imaging in Localized Prostate Cancer: Correlation With Multiparametric MRI and Histopathology.

Turkbey B, Mena E, Lindenberg L, Adler S, Bednarova S, Berman R, Ton AT, McKinney Y, Eclarinal P, Hill C, Afari G, Bhattacharyya S, Mease RC, Merino MJ, Jacobs PM, Wood BJ, Pinto PA, Pomper MG, Choyke PL.

Clin Nucl Med. 2017 Oct;42(10):735-740. doi: 10.1097/RLU.0000000000001804.

11.

Imaging Macrophage Accumulation in a Murine Model of Chronic Pancreatitis with 125I-Iodo-DPA-713 SPECT/CT.

Foss CA, Liu L, Mease RC, Wang H, Pasricha P, Pomper MG.

J Nucl Med. 2017 Oct;58(10):1685-1690. doi: 10.2967/jnumed.117.189571. Epub 2017 May 18.

12.

A PSMA-targeted theranostic agent for photodynamic therapy.

Chen Y, Chatterjee S, Lisok A, Minn I, Pullambhatla M, Wharram B, Wang Y, Jin J, Bhujwalla ZM, Nimmagadda S, Mease RC, Pomper MG.

J Photochem Photobiol B. 2017 Feb;167:111-116. doi: 10.1016/j.jphotobiol.2016.12.018. Epub 2016 Dec 18.

13.

Development of Radiolabeled Ligands Targeting the Glutamate Binding Site of the N-Methyl-d-aspartate Receptor as Potential Imaging Agents for Brain.

Tamborini L, Chen Y, Foss CA, Pinto A, Horti AG, Traynelis SF, De Micheli C, Mease RC, Hansen KB, Conti P, Pomper MG.

J Med Chem. 2016 Dec 22;59(24):11110-11119. Epub 2016 Dec 6.

14.

MR-Guided Delivery of Hydrophilic Molecular Imaging Agents Across the Blood-Brain Barrier Through Focused Ultrasound.

Airan RD, Foss CA, Ellens NP, Wang Y, Mease RC, Farahani K, Pomper MG.

Mol Imaging Biol. 2017 Feb;19(1):24-30. doi: 10.1007/s11307-016-0985-2.

15.

An improved synthesis of the radiolabeled prostate-specific membrane antigen inhibitor, [(18) F]DCFPyL.

Ravert HT, Holt DP, Chen Y, Mease RC, Fan H, Pomper MG, Dannals RF.

J Labelled Comp Radiopharm. 2016 Sep;59(11):439-50. doi: 10.1002/jlcr.3430. Epub 2016 Jul 29.

16.

[64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma.

Minn I, Koo SM, Lee HS, Brummet M, Rowe SP, Gorin MA, Sysa-Shah P, Lewis WD, Ahn HH, Wang Y, Banerjee SR, Mease RC, Nimmagadda S, Allaf ME, Pomper MG, Yang X.

Oncotarget. 2016 Aug 30;7(35):56471-56479. doi: 10.18632/oncotarget.10602.

17.

[(18)F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance.

Chen Y, Lisok A, Chatterjee S, Wharram B, Pullambhatla M, Wang Y, Sgouros G, Mease RC, Pomper MG.

Bioconjug Chem. 2016 Jul 20;27(7):1655-62. doi: 10.1021/acs.bioconjchem.6b00195. Epub 2016 Jun 24.

18.

(2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy.

Kiess AP, Minn I, Vaidyanathan G, Hobbs RF, Josefsson A, Shen C, Brummet M, Chen Y, Choi J, Koumarianou E, Baidoo K, Brechbiel MW, Mease RC, Sgouros G, Zalutsky MR, Pomper MG.

J Nucl Med. 2016 Oct;57(10):1569-1575. Epub 2016 May 26.

19.

PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.

Rowe SP, Macura KJ, Mena E, Blackford AL, Nadal R, Antonarakis ES, Eisenberger M, Carducci M, Fan H, Dannals RF, Chen Y, Mease RC, Szabo Z, Pomper MG, Cho SY.

Mol Imaging Biol. 2016 Jun;18(3):411-9. doi: 10.1007/s11307-016-0957-6.

20.

Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.

Ray Banerjee S, Chen Z, Pullambhatla M, Lisok A, Chen J, Mease RC, Pomper MG.

Bioconjug Chem. 2016 Jun 15;27(6):1447-55. doi: 10.1021/acs.bioconjchem.5b00679. Epub 2016 May 9.

21.

[(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA).

Yang X, Mease RC, Pullambhatla M, Lisok A, Chen Y, Foss CA, Wang Y, Shallal H, Edelman H, Hoye AT, Attardo G, Nimmagadda S, Pomper MG.

J Med Chem. 2016 Jan 14;59(1):206-18. doi: 10.1021/acs.jmedchem.5b01268. Epub 2015 Dec 16.

22.

Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer.

Rowe SP, Macura KJ, Ciarallo A, Mena E, Blackford A, Nadal R, Antonarakis ES, Eisenberger MA, Carducci MA, Ross AE, Kantoff PW, Holt DP, Dannals RF, Mease RC, Pomper MG, Cho SY.

J Nucl Med. 2016 Jan;57(1):46-53. doi: 10.2967/jnumed.115.163782. Epub 2015 Oct 22.

23.

Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor.

Yang X, Minn I, Rowe SP, Banerjee SR, Gorin MA, Brummet M, Lee HS, Koo SM, Sysa-Shah P, Mease RC, Nimmagadda S, Allaf ME, Pomper MG.

Oncotarget. 2015 Oct 20;6(32):33733-42. doi: 10.18632/oncotarget.5254.

24.

Prostate-specific membrane antigen as a target for cancer imaging and therapy.

Kiess AP, Banerjee SR, Mease RC, Rowe SP, Rao A, Foss CA, Chen Y, Yang X, Cho SY, Nimmagadda S, Pomper MG.

Q J Nucl Med Mol Imaging. 2015 Sep;59(3):241-68. Epub 2015 Jul 24. Review.

25.

Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen.

Kiess AP, Minn I, Chen Y, Hobbs R, Sgouros G, Mease RC, Pullambhatla M, Shen CJ, Foss CA, Pomper MG.

J Nucl Med. 2015 Sep;56(9):1401-1407. doi: 10.2967/jnumed.115.155929. Epub 2015 Jul 16.

26.

¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.

Rowe SP, Gage KL, Faraj SF, Macura KJ, Cornish TC, Gonzalez-Roibon N, Guner G, Munari E, Partin AW, Pavlovich CP, Han M, Carter HB, Bivalacqua TJ, Blackford A, Holt D, Dannals RF, Netto GJ, Lodge MA, Mease RC, Pomper MG, Cho SY.

J Nucl Med. 2015 Jul;56(7):1003-1010. doi: 10.2967/jnumed.115.154336. Epub 2015 Jun 11.

27.

Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.

Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, Antonarakis ES, Fan H, Dannals RF, Chen Y, Mease RC, Vranesic M, Bhatnagar A, Sgouros G, Cho SY, Pomper MG.

Mol Imaging Biol. 2015 Aug;17(4):565-74. doi: 10.1007/s11307-015-0850-8.

28.

Molecular imaging of inflammation in the ApoE -/- mouse model of atherosclerosis with IodoDPA.

Foss CA, Bedja D, Mease RC, Wang H, Kass DA, Chatterjee S, Pomper MG.

Biochem Biophys Res Commun. 2015 May 22;461(1):70-5. doi: 10.1016/j.bbrc.2015.03.171. Epub 2015 Apr 6.

29.

Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates.

Banerjee SR, Foss CA, Pullambhatla M, Wang Y, Srinivasan S, Hobbs RF, Baidoo KE, Brechbiel MW, Nimmagadda S, Mease RC, Sgouros G, Pomper MG.

J Nucl Med. 2015 Apr;56(4):628-34. doi: 10.2967/jnumed.114.149062. Epub 2015 Feb 26.

30.

[(125)I]Iodo-ASEM, a specific in vivo radioligand for α7-nAChR.

Gao Y, Mease RC, Olson TT, Kellar KJ, Dannals RF, Pomper MG, Horti AG.

Nucl Med Biol. 2015 May;42(5):488-493. doi: 10.1016/j.nucmedbio.2014.12.008. Epub 2014 Dec 20.

31.

Real-time, near-infrared fluorescence imaging with an optimized dye/light source/camera combination for surgical guidance of prostate cancer.

Neuman BP, Eifler JB, Castanares M, Chowdhury WH, Chen Y, Mease RC, Ma R, Mukherjee A, Lupold SE, Pomper MG, Rodriguez R.

Clin Cancer Res. 2015 Feb 15;21(4):771-80. doi: 10.1158/1078-0432.CCR-14-0891. Epub 2014 Dec 12.

32.

Radioiodinated DPA-713 imaging correlates with bactericidal activity of tuberculosis treatments in mice.

Ordonez AA, Pokkali S, DeMarco VP, Klunk M, Mease RC, Foss CA, Pomper MG, Jain SK.

Antimicrob Agents Chemother. 2015 Jan;59(1):642-9. doi: 10.1128/AAC.04180-14. Epub 2014 Nov 17.

33.

Imaging Enterobacteriaceae infection in vivo with 18F-fluorodeoxysorbitol positron emission tomography.

Weinstein EA, Ordonez AA, DeMarco VP, Murawski AM, Pokkali S, MacDonald EM, Klunk M, Mease RC, Pomper MG, Jain SK.

Sci Transl Med. 2014 Oct 22;6(259):259ra146. doi: 10.1126/scitranslmed.3009815.

34.

AEG-1 promoter-mediated imaging of prostate cancer.

Bhatnagar A, Wang Y, Mease RC, Gabrielson M, Sysa P, Minn I, Green G, Simmons B, Gabrielson K, Sarkar S, Fisher PB, Pomper MG.

Cancer Res. 2014 Oct 15;74(20):5772-81. doi: 10.1158/0008-5472.CAN-14-0018. Epub 2014 Aug 21.

35.

Bridged cyclams as imaging agents for chemokine receptor 4 (CXCR4).

Woodard LE, De Silva RA, Behnam Azad B, Lisok A, Pullambhatla M, G Lesniak W, Mease RC, Pomper MG, Nimmagadda S.

Nucl Med Biol. 2014 Aug;41(7):552-61. doi: 10.1016/j.nucmedbio.2014.04.081. Epub 2014 Apr 21.

36.

A red-shifted fluorescent substrate for aldehyde dehydrogenase.

Minn I, Wang H, Mease RC, Byun Y, Yang X, Wang J, Leach SD, Pomper MG.

Nat Commun. 2014 Apr 23;5:3662. doi: 10.1038/ncomms4662.

37.

Evaluation of prostate-specific membrane antigen as an imaging reporter.

Castanares MA, Mukherjee A, Chowdhury WH, Liu M, Chen Y, Mease RC, Wang Y, Rodriguez R, Lupold SE, Pomper MG.

J Nucl Med. 2014 May;55(5):805-11. doi: 10.2967/jnumed.113.134031. Epub 2014 Apr 3.

38.

⁶⁴Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer.

Banerjee SR, Pullambhatla M, Foss CA, Nimmagadda S, Ferdani R, Anderson CJ, Mease RC, Pomper MG.

J Med Chem. 2014 Mar 27;57(6):2657-69. doi: 10.1021/jm401921j. Epub 2014 Mar 7.

39.

Heterobivalent agents targeting PSMA and integrin-αvβ3.

Shallal HM, Minn I, Banerjee SR, Lisok A, Mease RC, Pomper MG.

Bioconjug Chem. 2014 Feb 19;25(2):393-405. doi: 10.1021/bc4005377. Epub 2014 Jan 22.

40.

Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA).

Ray Banerjee S, Pullambhatla M, Foss CA, Falk A, Byun Y, Nimmagadda S, Mease RC, Pomper MG.

J Med Chem. 2013 Aug 8;56(15):6108-21. doi: 10.1021/jm400823w. Epub 2013 Jul 22.

41.

Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitors.

Kostova MB, Rosen DM, Chen Y, Mease RC, Denmeade SR.

J Med Chem. 2013 Jun 13;56(11):4224-35. doi: 10.1021/jm301718c. Epub 2013 Jun 4.

42.

Radiochemical synthesis and in vivo evaluation of [18F]AZ11637326: an agonist probe for the α7 nicotinic acetylcholine receptor.

Ravert HT, Dorff P, Foss CA, Mease RC, Fan H, Holmquist CR, Phillips E, McCarthy DJ, Heys JR, Holt DP, Wang Y, Endres CJ, Dannals RF, Pomper MG.

Nucl Med Biol. 2013 Aug;40(6):731-9. doi: 10.1016/j.nucmedbio.2013.04.005. Epub 2013 May 13.

PMID:
23680470
43.

Synthesis and Biological Evaluation of Substrate-Based Imaging Agents for the Prostate-Specific Membrane Antigen.

Byun Y, Pullambhatla M, Wang H, Mease RC, Pomper MG.

Macromol Res. 2013 May 1;21(5):565-573.

44.

PET imaging in prostate cancer: focus on prostate-specific membrane antigen.

Mease RC, Foss CA, Pomper MG.

Curr Top Med Chem. 2013;13(8):951-62. Review.

45.

Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.

Cho SY, Gage KL, Mease RC, Senthamizhchelvan S, Holt DP, Jeffrey-Kwanisai A, Endres CJ, Dannals RF, Sgouros G, Lodge M, Eisenberger MA, Rodriguez R, Carducci MA, Rojas C, Slusher BS, Kozikowski AP, Pomper MG.

J Nucl Med. 2012 Dec;53(12):1883-91. doi: 10.2967/jnumed.112.104661.

46.

Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen.

Chen Y, Pullambhatla M, Banerjee SR, Byun Y, Stathis M, Rojas C, Slusher BS, Mease RC, Pomper MG.

Bioconjug Chem. 2012 Dec 19;23(12):2377-85. doi: 10.1021/bc3003919. Epub 2012 Dec 4.

47.

[32P]ATP inhibits the growth of xenografted tumors in nude mice.

Cheng Y, Senthamizhchelvan S, Agarwal R, Green GM, Mease RC, Sgouros G, Huso DL, Pomper MG, Meltzer SJ, Abraham JM.

Cell Cycle. 2012 May 15;11(10):1878-82. doi: 10.4161/cc.19955. Epub 2012 May 15.

48.

GCPII imaging and cancer.

Foss CA, Mease RC, Cho SY, Kim HJ, Pomper MG.

Curr Med Chem. 2012;19(9):1346-59. Review.

49.

A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA).

Banerjee SR, Pullambhatla M, Shallal H, Lisok A, Mease RC, Pomper MG.

Oncotarget. 2011 Dec;2(12):1244-53.

50.

2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.

Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, Sgouros G, Mease RC, Pomper MG.

Clin Cancer Res. 2011 Dec 15;17(24):7645-53. doi: 10.1158/1078-0432.CCR-11-1357. Epub 2011 Oct 31.

Supplemental Content

Loading ...
Support Center